Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20969511 | 0.77 | TDP1 (0.39) | TDP1ALDH1A1MAPT | |
| SCHEMBL1282757 | 0.76 | TSHR (0.45) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL8781902 | 0.74 | TDP1 (0.42) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL2006527 | 0.74 | TDP1 (0.42) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL991835 | 0.73 | CASP1 (0.43) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL8869145 | 0.73 | CASP1 (0.43) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL10882651 | 0.73 | CASP1 (0.43) | CASP1TDP1ALDH1A1MAPT | |
| SCHEMBL7748899 | 0.71 | ALDH1A1 (0.37) | TDP1ALDH1A1MAPT | |
| SCHEMBL7748902 | 0.71 | ALDH1A1 (0.37) | TDP1ALDH1A1MAPT | |
| SCHEMBL10457950 | 0.71 | MAPT (0.41) | CASP1TDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CASP1 717/4885TDP1 2672/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.